Ernexa says ERNA-101 plus anti-PD-1 clears tumors in ovarian cancer preclinical study - ERNA News | RalliesErnexa says ERNA-101 plus anti-PD-1 clears tumors in ovarian cancer preclinical study
E
ERNA• Development timeline
- The company kept its timeline for an IND submission in Q3 2026.
- A first-in-human Phase 1 trial is expected to start in Q4 2026.
Preclinical ovarian cancer results
- Ernexa reported independent CRO validation of ERNA-101 combined with anti-PD-1 in an ovarian cancer model.
- The combination produced complete tumor clearance with durable survival in 10 of 15 animals, or 67%.
- No complete responses were seen in 45 animals across ERNA-101 alone, anti-PD-1 alone, or untreated control groups.
•
